March 1, 1984Journal of Clinical Oncology

A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma.

View Full Paper

Ask AI

Bookmark

Why the study?

Does high-dose methotrexate as postsurgical adjuvant treatment improve survival in patients with completely excised primary osteosarcoma?

Structured PICO

Does high-dose methotrexate as postsurgical adjuvant treatment improve survival in patients with completely excised primary osteosarcoma?

Population

n=38 patients with completely excised primary extremity or limb girdle osteosarcomas (37 amputations, one limb sparing procedure)

Intervention

High-dose methotrexate (HDMTX) regimen (vincristine, HDMTX, leucovorin) given at three-week intervals for one year, with planned dose escalations from 3 to 6 to 7.5 g/m2, plus regular follow-up

Comparator

Regular follow-up without primary adjuvant chemotherapy

Outcome

Survival and relapse-free survival at five yearshard clinical

This pilot study found no significant survival benefit for adjuvant high-dose methotrexate in osteosarcoma, though it was underpowered, highlighting the need for larger controlled trials.

Limitations

Low power to detect differences

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

No support for adjuvant high-dose methotrexate; leaves open efficacy in larger RCTs.

Cite This Study

Edmonson et al. (1984) studied this question.

synapsesocial.com/papers/6a7051cd26a7f98052dcd222 https://doi.org/10.1200/jco.1984.2.3.152

View Full Paper

Ask AI

Bookmark

A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma.

Structured PICO

Limitations

Discussion

Implication

Cite This Study

A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma.

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider